Global CRO Capabilities Quinta-Analytica offers in-house clinical testing, bioanalytics, pharmaceutical quality control, and analytical R&D support across small molecules, biologics, biosimilars, generics, and IMPs, with global pharma/biotech reach and full lifecycle coverage from early development to market.

Regulatory Trust Signals Certified and inspected across GCP, GLP, GMP standards with EMA and FDA oversight, including multiple FDA inspections in 2025, highlighting strong quality and compliance that can de-risk partner programs and support regulatory submissions.

Advanced Laboratories Recent UHPLC toolset launch positions Quinta as a technical differentiator, enabling faster, higher-resolution analytical testing to meet stringent PK/BE/BA requirements and shorten development timelines for customers.

Capacity and Flexibility In-house clinical units with substantial bed capacity (60+36) and diverse service lines, allowing integrated studies, timely project scaling, and single-source coordination for complex multi-study programs.

Strategic Affiliation Part of the Conscio Group with German leadership, suggesting potential cross-selling opportunities within the group, shared standards, and expanded geographic reach to support customers with multi-region regulatory needs.